Iberdomide

Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities[1][2].

Product Specifications

CAS Number

[1323403-33-3]

Product Name Alternative

CC-220

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Ligands for E3 Ligase; Molecular Glues

Type

Reference compound

Related Pathways

Apoptosis; PROTAC

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Iberdomide.html

Purity

99.54

Solubility

DMSO : 175 mg/mL (ultrasonic)

Smiles

O=C([C@@H](N(CC1=C2C=CC=C1OCC3=CC=C(CN4CCOCC4)C=C3)C2=O)CC5)NC5=O

Molecular Formula

C25H27N3O5

Molecular Weight

449.50

Precautions

H315, H319, H335

References & Citations

[1]Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34 (4) :1197-1201.|[2]Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2 (4) :354-369.